Pharmacogenetic testing for predicting methylphenidate treatment outcomes in childhood attention deficit hyperactivity disorder in Turkey: Focus on carboxylesterase 1, latrophilin-3, and catechol-o-methyltransferase.

Basit Öğe Kaydı
dc.authoridhttps://orcid.org/0000-0002-6514-0157
dc.authoridhttps://orcid.org/0009-0004-5184-4980
dc.authoridhttps://orcid.org/0000-0002-3850-2028
dc.authoridhttps://orcid.org/0000-0003-1833-1783
dc.authoridhttps://orcid.org/0000-0001-9057-9017
dc.authoridhttps://orcid.org/0000-0003-0446-4841
dc.authoridhttps://orcid.org/0000-0001-6450-5380
dc.authoridhttps://orcid.org/0000-0002-6183-9489
dc.authoridhttps://orcid.org/0000-0001-9598-8944
dc.authoridhttps://orcid.org/0000-0003-1864-2151
dc.authoridhttps://orcid.org/0000-0002-9972-5049
dc.contributor.authorSuzer Gamli, Ipek
dc.contributor.authorVan Veggel, Anne
dc.contributor.authorKaraaslan, Rabia Sevcan
dc.contributor.authorKuerec, Ajla Hodzic
dc.contributor.authorMarzoukah, Zeina
dc.contributor.authorAdak, Ibrahim
dc.contributor.authorBulut, Gulay
dc.contributor.authorTunc, Huseyin
dc.contributor.authorHizel, Candan Perry
dc.contributor.authorParlayan, Cuneyd
dc.contributor.authorEkinci, Ozalp
dc.contributor.authorVan Schaik, Ron
dc.contributor.authorAkin, Demet
dc.date.accessioned2025-03-13T09:01:08Z
dc.date.available2025-03-13T09:01:08Z
dc.date.issued2025-01-05
dc.departmentFakülteler, Tıp Fakültesi, Acil Tıp Bilimleri Bölümü
dc.description.abstractPharmacogenetic studies involving Carboxylesterase 1 (CES1), Latrophilin-3 (LPHN3), and Catechol-O-methyltransferase (COMT) revealed individual differences regarding therapeutic response in children with attention deficit hyperactivity disorder (ADHD) under methylphenidate (MPH) treatment. This study aimed to evaluate MPH's association with the adverse effect status in children and its relationship with CES1, LPHN3, and COMT in the Turkish population. The study included 102 children and adolescents with ADHD, who were categorized as responders, or the adverse effect group based on their treatment response. The Naranjo Adverse Drug Reaction Probability Scale evaluated the presence and severity of adverse effects. Saliva sample was taken from the patients and genotype distribution of CES1 rs3815583, CES1 rs2307227, LPHN3 rs6551665, LPHN3 rs1947274, LPHN3 rs6858066, LPHN3 rs2345039, and COMT rs4680 were examined. In the adverse effect group, instances of carrying the GG genotype in CES1 rs2307227, having G vs. T genotype and GG vs. GT were significantly higher. In LPHN3 rs2345039, carrying the C genotype vs. G was associated with a serious adverse effect. In COMT rs4680, individuals with the AA or GG genotype were significantly higher in the adverse effect group. Our study suggests a relationship between genetic polymorphisms and the side effect status in children receiving MPH.
dc.description.sponsorshipFunding agency : Australian Wool Innovation This work is supported by BeinGenetics Company. Bu çalışma BeinGenetics Şirketi tarafından desteklenmiştir.
dc.identifier.citationSuzer Gamli, I., Van Veggel, A., Karaaslan, R. S., Kuerec, A. H., Marzoukah, Z., Adak, I., Bulut, G., Tunc, H., Hizel, C. P., Parlayan, C., Ekinci, O., Van Schaik, R., & Akin, D. (2025). Pharmacogenetic Testing for Predicting Methylphenidate Treatment Outcomes in Childhood Attention Deficit Hyperactivity Disorder in Turkey: Focus on Carboxylesterase 1, Latrophilin-3, and Catechol-O-Methyltransferase. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, e33024. Advance online publication. https://doi.org/10.1002/ajmg.b.33024
dc.identifier.doi10.1002/ajmg.b.33024
dc.identifier.issn1552-4841
dc.identifier.issn1552-485X
dc.identifier.pmid39868802
dc.identifier.scopus2-s2.0-85216258306
dc.identifier.scopusqualityQ4
dc.identifier.urihttps://doi.org/10.1002/ajmg.b.33024
dc.identifier.urihttps://hdl.handle.net/20.500.14619/15137
dc.identifier.wosWOS:001406748400001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakScopus
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc.
dc.relation.ispartofAmerican Journal of Medical Genetics, Part B: Neuropsychiatric Genetics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectADHD
dc.subjectadverse effect
dc.subjectmethylphenidate
dc.subjectpharmacogenomics
dc.titlePharmacogenetic testing for predicting methylphenidate treatment outcomes in childhood attention deficit hyperactivity disorder in Turkey: Focus on carboxylesterase 1, latrophilin-3, and catechol-o-methyltransferase.
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
Ä°sim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
Ä°ndir

Koleksiyon

Tıp Fakültesi Koleksiyonu